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Table S1. V(D)J rearrangements and sequences of anti-ZEDIII antibodies that do 
cluster in clones. Excel file. Related to Figure 2. 
 
Table S2. V(D)J rearrangements and CDR3 sequences of anti-ZEDIII antibodies 
that do not cluster in clones (singlets). Excel file. Related to Figure 2. 
 
Table S3. List of primers for cloning recombinant antibodies by the SLIC method. 
Related to Methods. 
 
Table S4. List of primers for the generation of RVP expression constructs. Related 
to Methods. 
 
Table S5. Data collection and refinement statistics. Related to Figure 5. 
 






Table S3. List of primers for cloning recombinant antibodies by the SLIC method. 




Primer ID Primer sequence Best V or J gene 
segment match 
Human antibody heavy chain (forward) 
p1355DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAG VH 1 
p1356DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG VH 1/5 
p1357DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG VH 1-18 
p1358DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG VH 1-24 
p1359DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG VH 3 
p1360DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG VH 3-11 
p1361DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG VH 3-23 
p1362DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG VH 3-33 
p1363DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG VH 3-9 
p1364DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG VH 4 
p1365DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG VH 4-34 
p1366DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG VH 4-39 
p1367DFR 5’CTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG VH 6-1 
Human antibody heavy chain (reverse) 
p1370DFR 5’CCGATGGGCCCTTGGTCGACGCTGAGGAGACGGTGACCAG JH 1/2 
p1371DFR 5’CCGATGGGCCCTTGGTCGACGCTGAAGAGACGGTGACCATTG JH 3 
p1372DFR 5’CCGATGGGCCCTTGGTCGACGCTGAGGAGACGGTGACCAG JH 4/5 
p1373DFR 5’CCGATGGGCCCTTGGTCGACGCTGAGGAGACGGTGACCGTG JH 6 
Human antibody light chain kappa (forward) 
p1379DFR 5’GTAGCAACTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC VK 1-5 
p1380DFR 5’GTAGCAACTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT VK 1-9 
p1381DFR 5’GTAGCAACTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC VK 1D-43 
p1382DFR 5’GTAGCAACTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC VK 2-2 
p1383DFR 5’GTAGCAACTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC VK 2-28 
p1384DFR 5’GTAGCAACTGCAACCGGTGTACATGGGGATGTTGTGATGACTCAGTC VK 2-30 
p1385DFR 5’GTAGCAACTGCAACCGGTGTACATTCAGAAATTGTGTTGACACAGTC VK 3-11 
p1386DFR 5’GTAGCAACTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC VK 3-15 
p1387DFR 5’GTAGCAACTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT VK 3-20 
p1388DFR 5’GTAGCAACTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC VK 4-1 
Human antibody light chain kappa (reverse) 
p1390DFR GAAGACAGATGGTGCAGCCACCGTACGTTTGATYTCCACCTTGGTC JK 1/4 
p1391DFR GAAGACAGATGGTGCAGCCACCGTACGTTTGATCTCCAGCTTGGTC JK 2 
p1392DFR GAAGACAGATGGTGCAGCCACCGTACGTTTGATATCCACTTTGGTC JK 3 
p1393DFR GAAGACAGATGGTGCAGCCACCGTACGTTTAATCTCCAGTCGTGTC JK 5 
Human antibody light chain lambda (forward) 
p1402DFR CTAGTAGCAACTGCAACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG VL 1 
p1403DFR CTAGTAGCAACTGCAACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG VL 2 
p1404DFR CTAGTAGCAACTGCAACCGGTTCTGTGACCTCCTATGAGCTGACWCAG VL 3 
p1405DFR CTAGTAGCAACTGCAACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA VL 4/5 
p1406DFR CTAGTAGCAACTGCAACCGGTTCTTGGGCCAATTTTATGCTGACTCAG VL 6 
p1407DFR CTAGTAGCAACTGCAACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG VL 7/8 
Human antibody light chain lambda (reverse) 












Primer ID Primer sequence Comments 
Mutation of BspHI sites in pZIKV/HPF/CprME to generate pZIKV/HPF/CprM*E* 
RU-O-24303 GTTAAGGGATTTTGGACATGAGATTATC BspHI at nt 6419 forward 
RU-O-24304 GATAATCTCATGTCCAAAATCCCTTAAC BspHI at nt 6419 reverse 
RU-O-24309 CTTGGTTGAGTACTCACCAGTCA Reverse outer (for 6419) 
RU-O-24310 GAAGACTACAGCGTCGCCAG Forward outer (for 6419) 
RU-O-24305 GTTATTGTCTCATGCGCGGATAC BspHI at nt 7427 forward 
RU-O-24306 GTATCCGCGCATGAGACAATAAC BspHI at nt 7427 reverse 
RU-O-24307 CTTCATGCAATTGTCGGTCAAGCC Reverse outer (for 7427) 
RU-O-24308 TGACTGGTGAGTACTCAACCAAG Forward outer (for 7427) 
Generation of E mutations in pZIKV/HPF/CprM*E* 
RU-O-24998 AGGAGTCGGGGCGAAGAAGATCAC E393A forward 
RU-O-24999 GTGATCTTCTTCGCCCCGACTCCT E393A reverse 
RU-O-25000 AGGAGTCGGGGAGGCGAAGATCAC K394A forward 







Generation of pDENV1/PUO-359/CprME 
RU-O-24611 CTTGACCGACAATTGCATGAAG 
 




CMV promoter-Capsid fusion 
reverse 




E C-terminus-SacII site 
reverse 
Generation of pZIKV/HPF-CprM/MR766-E 
RU-O-24994 CAAAGAGTGGTTCCATGACATCCCATTG BspHI site mutation forward 

















Table S5. Data collection and refinement statistics. Related to Figure 5. 	
  Z006–ZIKV EDIII Z004–DENV1 EDIII 
Data Collection   
Resolution Range (Å) 29.75 - 3.0 (3.107 - 3.0) 37.11 - 3.0 (3.107 - 3.0) 
Space group R 3 2 :H P 43 21 2 
Cell dimensions   
       a, b, c (Å) 385.08, 385.08, 56.64  74.23, 74.23, 190.76 
       α, β, γ (º) 90, 90, 120 90, 90, 90 
Total reflections 170795 (25781) 121867 (20556) 
Unique reflections 31520 (3151) 11154 (1101) 
Multiplicity 5.4 (5.6) 10.9 (11.6) 
Completeness (%) 98.71 (99.78) 98.30 (99.73) 
Mean I/s(I) 8.2 (2.3) 11.1 (3.3) 
Wilson B-factor (Å2) 77.8 58.7 
Rmerge 0.120 (0.598) 0.179 (0.829) 
Rpim 0.083 (0.410) 0.079 (0.358) 
CC1/2 0.992 (0.779) 0.994 (0.869) 
   
Refinement   
Rwork/Rfree 0.212/ 0.257 0.236/ 0.281 
Number of atoms 7905 3904 
       Macromolecules 7892 3904 
        Ligand 13 0 
Protein residues 1051 513 
RMS (bonds) (Å) 0.007 0.003 
RMS (angles) (˚) 0.85 0.64 
Ramachandran favored (%) 90.8 93.0 
Ramachandran allowed (%) 7.6 6.8 
Ramachandran outliers (%) 1.6 0.2 
Rotamer outliers (%) 8.8 0.9 
Clashscore 9.2 2.5 
Average B-factor (Å2) 103.78 59.31 
Number of TLS groups 6 17 
 






Table S6. Antibody-antigen contacts. Related to Figure 5.  
Contacts are defined as residues in which any atom is within 4 Å of an atom from a 
residue on the interacting partner using AntibodyDatabase (West et al., 2013). The table 
is organized by antibody residue, listing all antigen residues contacted by each antibody 
residue (ordered by contact distance). Antibody residues are highlighted when 
corresponding interactions occur in both complexes. For the highlighted interactions 
additional information is listed including the antibody residue’s origin in V(D)J 
recombination and the residue distribution at that antibody position in the sequenced 
antibody clones. 
 	






S56 L307 S56 M301,	V300
T57 S306
Y58 L307,	S306,	T309 3.07 Y58 M301,	V300,	T303 2.54 Tyr-OH	w/	antigen	backbone	oxygen V	Germline 68	Y,	1	W
R96 E393 3.44 R96 E384 2.55 electrostatic/salt	bridge N	addition 68	R,	1	Q
S97 K395,	G392,	E393
N98 L352,	G392,	V391,	K395
G99 G392 R99 G383,	S338,	A382
W100 T309,	K394 G100 G383




Q27 T335 3.28 Q27 T329 3.96 V	Germline 58	Q,	6	H,	5	R
S30 E327
W32 K394,	A311 3.08 W32 K385,	S305,	E327 3.37 hydrophobic	(plus	cation-pi) V	Germline 68	W,	1	L
Y49 E393
Q50 E393
Y91 K394,	E393 2.45 F91 K385 2.28 hydrophobic	(plus	Tyr-OH/Glu	H-bond	for	ZIKV) V	Germline/SHM 57	Y,	12	F
S92 A310,	K394,	T309 3.03 Y92 G328,	K385,	327,	G304,	T303
T93 T335,	G334,	D336,	A310,	T309 3.22 S93 T329,	T303,	G328	 2.68 H-bond	to	antigen	backbone	nitrogen V	Germline/SHM 42	S,	23	T,	3	N,	1	G
F94 T309,	D336 3.42 V94 T303,	T329,	D330 3.1 antigen	sidechain	H-bond	to	LC	backbone	plus	vDW	for	antibody	sidechain 43	Y,	13	F,	12	V,	1	S
W96 T303
HC
LC
	
 
